Ketryx, the AI-native compliance platform for safety-critical product development, announced record momentum as the company enters 2026, driven by surging demand for validated AI in the medical device, digital health, diagnostics, and life sciences sectors. The company reported that four of the top five Fortune 500 MedTech companies now run on Ketryx, and its platform supports products reaching more than 100 million patients worldwide.
This achievement highlights a significant shift in the industry: organizations are moving from AI experimentation to enterprise-wide deployment, requiring robust compliance and validation frameworks. Ketryx’s platform enables these companies to accelerate product development without compromising safety or regulatory compliance, addressing a critical need as AI becomes more integrated into healthcare technologies.
The company’s AI-native platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles, all while maintaining existing workflows. By leveraging Ketryx AI Agents, teams can reduce manual work by 90 percent and close compliance gaps, thereby improving both speed and quality across the product lifecycle.
Ketryx’s rapid adoption reflects the broader industry trend where validated AI is no longer optional but essential for maintaining competitiveness in safety-critical environments. As regulatory bodies increasingly emphasize AI validation, companies that adopt platforms like Ketryx gain a strategic advantage by streamlining compliance and reducing time-to-market.
For more information, visit www.ketryx.com. The full announcement, including downloadable images and bios, is available here.
